Clinical trials: Anti-coagulation Therapy
Ischemic Stroke
Combination Anti-Platelet and Anti-Coagulation Treatment After Lysis of Ischemic Stroke Trial (CATALIST)
Ischemic stroke is caused by a blood clot that blocks the flow of blood to the brain and damages brain cells. The clot, or thrombus, is made up of platelets and fibrin.
- Trial name
- CATALIST (NCT00061373)
- Testing
- Aspirin, tinzaparin sodium, eptifibatide
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Paroxysmal Atrial Fibrillation
Oral Anticoagulation Therapy Pilot Study
The objective of this study is to determine the safety of discontinuing oral anticoagulation therapy in high risk patients who have had a successful cardiac ablation and remain AF recurrence free for 3 months post ablation.
- Trial name
- OAT (NCT01959425)
- Testing
- Off OAT Group (Test), On OAT Group (Control)
- Volunteers
- 80 people
- Sponsor
- Biosense Webster, Inc.
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
Coronary Artery Disease
(A Novel Pharmacologic Regime for Elective Percutaneous Coronary Intervention)
The hypothesis: Low dose intracoronary unfractionated heparin is as effective and safe as standard dose intravenous unfractionated heparin on patients with elective percutaneous coronary intervention.
- Trial name
- REDUCED (NCT01031095)
- Testing
- coronary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Bursa Postgraduate Hospital
Anticoagulant Therapy
In Vitro Diagnostic Test for DOAC in Urine
This trial is conducted to assess the performance and handling of the in vitro diagnostic (IVD) device for oral direct factor Xa and thrombin inhibitors from urine samples of patients on treatment with direct oral anticoagulants…
- Trial name
- PADOASU (NCT03182829)
- Testing
- DOAC Dipstick
- Where
- 18 sites in Germany
- Volunteers
- 880 people
- Sponsor
- Doasense GmbH
Dementia, Cognition Disorders
Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
Patients will be screened at Intermountain Medical Center and at Intermountain-affiliated anticoagulation clinics in the Salt Lake City region. Patients with non-valvular atrial fibrillation will be considered for study.
- Conditions
- Dementia, Cognition Disorders, Cerebral Ischemic Events
- Trial name
- CAF (NCT03061006)
- Testing
- Dabigatran Etexilate, Warfarin
- Where
- United States
- Volunteers
- 101 people
- Sponsor
- Intermountain Health Care, Inc.
Atrial Fibrillation
Adherence to New Oral Anticoagulation Therapy in Turkey
This study will compose a national database of drug adherence and investigate the factors that affect drug adherence in patients taking new oral anticoagulation therapy in Turkish Population.
- Trial name
- NOAC-TR (NCT02480920)
- Where
- Turkey (Türkiye)
- Volunteers
- 2,738 people
- Sponsor
- Cardiovascular Academy Society, Turkey
Pulmonary Embolism, Thrombotic Disease
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary Embolism
This is a Phase 1b, double-blind (participants and Investigators), placebo-controlled, randomized, single-ascending dose, multi-center study to assess the safety, efficacy, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT02923115
- Testing
- DS-1040b, Enoxaparin
- Where
- 46 sites in United States, Austria and 6 more
- Volunteers
- 134 people
- Sponsor
- Daiichi Sankyo
Atrial Fibrillation, Atrial Flutter
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and…
- Conditions
- Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial
- Trial name
- IMPACT (NCT00559988)
- Testing
- Home Monitoring Guided OAC, Physician-Directed OAC
- Where
- 80 sites in United States, Australia and 4 more
- Volunteers
- 2,718 people
- Sponsor
- Biotronik, Inc.
COVID 19 Associated Coagulopathy
Covid-19 Associated Coagulopathy
This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who…
- Trial name
- NCT04360824
- Testing
- Intermediate dose thromboprophylaxis, Standard of Care thromboprophylaxis
- Where
- 2 sites in United States
- Volunteers
- 176 people
- Sponsor
- University of Iowa
Cerebral Vein Thrombosis, Deep Vein Thrombosis
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
This randomized phase III trial studies the best dose of apixaban and how well it works in preventing secondary cancer related venous thrombosis in cancer patients who have completed anticoagulation therapy.
- Conditions
- Cerebral Vein Thrombosis, Deep Vein Thrombosis, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT03080883
- Testing
- Apixaban
- Where
- 32 sites in United States
- Volunteers
- 370 people
- Sponsor
- Academic and Community Cancer Research United
Atrial Fibrillation, AFib
Stroke Feasibility Study
This is a feasibility study to assess the safety and efficacy of the AtriCure AtriClip when placed via Minimally Invasive Surgical Deployment to the Left Atrial Appendage.
- Trial name
- NCT01997905
- Testing
- AtriClip LAA Exclusion Device
- Where
- 7 sites in United States
- Volunteers
- 13 people
- Sponsor
- AtriCure, Inc.
Upper Gastrointestinal Bleeding
Anticoagulation With Enhanced Gastrointestinal Safety (AEGIS) Trial
This is a pragmatic, single center, feasibility pilot cluster randomized trial with embedded individual randomization to evaluate implementation strategies to increase the use of evidence-based practices to reduce upper…
- Trial name
- AEGIS (NCT05085405)
- Testing
- Clinician notification, Clinician Notification with Nurse Facilitation, Clinician Notification / Patient Activation
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Michigan
Atrial Fibrillation (AF), Stroke
Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation
The purpose of the ANT-006 study is to evaluate the bleeding profile of abelacimab relative to rivaroxaban in patients with atrial fibrillation (AF) at moderate-to-high risk of stroke.
- Trial name
- AZALEA-TIMI 71 (NCT04755283)
- Testing
- Abelacimab, Rivaroxaban
- Where
- 92 sites in United States, Canada and 5 more
- Volunteers
- 1,287 people
- Sponsor
- Anthos Therapeutics, Inc.
Atrial Fibrillation, Medication Adherence
Keep it SIMPLE: Improving Anti-Coagulation Medication Adherence
This is an interventional study designed to develop patient focused strategies that improve adherence to anticoagulant medication in patients with non-valvular atrial fibrillation (AF).
- Trial name
- NCT02690649
- Testing
- Health Messaging (Non-Procedural)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Tammy Toscos
Pulmonary Embolism, Deep Vein Thrombosis
Study to Develop a Reliable Nomogram That Incorporates Clinical and Genetic Information
In this research study, the investigators are trying to find a better way to set the dose of a common blood-thinning medication.
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Atrial Fibrillation
- Trial name
- NCT00401414
- Testing
- Warfarin
- Where
- 2 sites in United States
- Volunteers
- 344 people
- Sponsor
- Brigham and Women's Hospital
Heart Valve Disease
D-Dimer Determined Anticoagulation INTENSITY in Patients With Mechanical Valve Replacement
The optimal intensity of oral anticoagulation in China patients undergoing mechanical valve replacements is still controversial due to the different risk profiles of thrombophilia and bleeding in Chinese patients.
- Trial name
- 3D-INTENSITY (NCT01996657)
- Testing
- Warfarin
- Where
- 2 sites in China
- Volunteers
- 772 people, healthy volunteers welcome
- Sponsor
- Wuhan Asia Heart Hospital
Atrial Fibrillation
Anticoagulation Therapy in the Very Old
This study is designed to evaluate the efficacy and safety of warfarin anticoagulation in the very old and attempt to identify risk factors which may impede safe and effective anticoagulation.
- Trial name
- ATIVO (NCT03103763)
- Testing
- Warfarin
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Robert Stein
Inflammation, Coagulation
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
The purpose of this study is to evaluate the effects of pharmacologic FXa inhibition (via edoxaban 30 mg daily) on inflammation, as reflected in plasma Interleukin-6 levels.
- Conditions
- Inflammation, Coagulation, HIV Infection
- Trial name
- TACTICAL-HIV (NCT02339415)
- Testing
- Edoxaban 30mg daily
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Hennepin Healthcare Research Institute